Avedro, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally processed more efficiently than claims using a miscellaneous code (J3490), which requires manual review. These Photrexa formulations are the only drugs approved by the U.S. Food and Drug Administration (FDA) for use in conjunction with the KXL System in corneal collagen cross-linking to treat progressive keratoconus and corneal ectasia following refractive surgery. CMS’ preliminary decision was announced at their public meeting held on May 15, 2018, and is expected to be finalized and announced in November of 2018, with new or revised codes becoming effective on January 1, 2019.